Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a Study of IMR-687 in Healthy Adult Volunteers
NCT02998450Phase 1Completed
- Sponsor
- Cardurion Pharmaceuticals
- Start
- Oct 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tovinontrine in sickle cell disease (SCD) and beta thalassemia (6 cohorts), sponsored by Cardurion Pharmaceuticals. Primary endpoints: Number of participants with treatment emergent adverse events and serious adverse events at 5 Days, Number of participants with clinically significant changes from baseline in vital signs and 4 more. Started Oct 2016; status: completed.
02
Drugs
tovinontrine
03
Conditions
sickle cell disease (SCD)beta thalassemia
Beyond the preview
Go deeper on NCT02998450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998450.